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Background: Pregnant women with asthma are recommended to maintain optimal therapeutic management
during pregnancy. Uncontrolled, symptomatic asthma may increase the risk of adverse peri-natal outcomes; thus
adequate regular anti-asthmatic treatment must be given to provide optimal asthma control during pregnancy.
However, doubts about the safety of asthmatic drugs can affect pregnant asthmatic patients’ drug compliance. The
aim of this study was to assess behavioral differences in drug compliance among pregnant asthmatic patients.
Methods: Thirty two asthmatic and 121 healthy pregnant women were enrolled in the study. Structured
face-to-face interviews were conducted after delivery. The interviews included disease characteristics, drug
compliance and patients’ own perspective for asthma status prior to and during pregnancy. In addition, medical
and pregnancy history, pregnancy complications and outcomes, and newborn characteristics were recorded.
Results: In our study group the rates of hospitalization, emergency room visits and systemic steroid use in the year
before pregnancy were 13%, 46.9% and 18.8%, respectively. The rate of regular asthma medication use was only
32% at that period and increased to 44% during pregnancy. However, hospitalization, emergency room visits,
systemic steroid usage rates remained unchanged and according to patients’ own evaluations, 44% of asthmatics
pointed out that their asthma had worsened during pregnancy. No statistically significant difference was detected
in terms of pregnancy/labour complication between asthmatic and non-asthmatics.
Conclusions: Contrary to some previous studies, in our study regular use of asthma drugs increased during
pregnancy. The uncontrolled condition of their asthma before and during pregnancy and the idea that their
asthma worsened during pregnancy might force the patients to use medication more regularly.
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Asthma is one of the most common chronic medical
conditions, accounting for complications in up to 8% of
pregnant women [1]. Women with well-controlled
asthma during pregnancy have been reported to have
healthy pregnancy periods with excellent maternal and
peri-natal outcomes. Treatment strategies do not differ
between pregnant and non-pregnant asthmatic women
and include the medications given for the maintenance
and reliever therapy and for the treatment of asthma
attacks as well [2]. However, asthma treatment during* Correspondence: insu2004@yahoo.com
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reproduction in any medium, provided the orpregnancy has led to discussion concerning medications
and complications of pregnancy. These concerns usually
lead to a behavioral change in pregnant asthmatics
against the medications that they had previously used.
Results from research seem to corroborate this. One
study reported that doubts about safety and possible
teratogenicity of medications lead 40% of pregnant
women to reduce or cease asthma medications, particu-
larly in the first trimester, which results in an increase in
the consumption of rescue medication, an increased
number of exacerbations, and reduced asthma control in
pregnant asthmatics with moderate to severe disease [2].
Similarly, in another study, 39% of asthmatic women
either discontinued their asthma medications or reduced
their dosage during pregnancy [3]. The authors alsoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(ICS) had concerns about the possibility of birth defects
occurring if they became pregnant [3]. Furthermore, it
was reported in another study that women with asthma
significantly decrease their asthma medication use from
five to 13 weeks of pregnancy. During the first trimester,
there was a 23% decline in ICS prescriptions, a 13% decline
in short-acting beta-agonist (SABA) prescriptions, and a
54% decline in rescue corticosteroid prescriptions [4].
It is well known that there are regional and cultural
differences in the control of asthma and drug compliance
[5]. In this study, we sought to observe the behavior of
pregnant women with asthma regarding drug usage in a
real life setting in our country. To the best of our know-
ledge, to date there have been no studies in our population
examining how drug compliance changes in asthmatic
pregnant patients. Therefore, the aim of this study was to




One hundred and fifty-three pregnant women admitted
to a Women’s Health Training and Research Hospital in
their third trimester were included in this cross-sectional
study. Subjects were randomly selected at the Department
of Obstetrics and Gynecology. Four consecutive non-
asthmatic pregnant women were included for each
asthmatic pregnant woman. All women had been admit-
ted to the hospital for delivering. No asthmatic pregnant
had been followed for asthma management by the chest
physicians in the study during her pregnancy. Asthmatic
pregnants were selected according to the presence of a
history of physician-diagnosed asthma, a physician report
confirming asthma diagnosis and use of asthma medication
for a period of at least 1 year before pregnancy. Following
this evaluation, the patients were allocated into two groups;
group I consisted of asthmatic pregnants (n = 32),
and group II was comprised of non-asthmatic pregnants
(n = 121). Structured face-to-face interviews were
conducted via a questionnaire. The interviews were
performed by a physician within 24 hours of delivery,
and the patients’ demographics and disease character-
istics, and asthma medication use before and during
pregnancy were evaluated by the same physician. Also
the number of hospitalizations, admission to an emergency
department, use of oral steroids because of asthma, asthma
medications, regular drug use, and the patients’ views on
their asthma status before and during pregnancy were
recorded. In this study, asthma status was only evaluated
from patients’ perspective. In the questionnaire, they were
asked to judge their asthma status before and during preg-
nancy and they made a decision whether it got worse or
improved or stayed stable. Like other parameters listedabove, regular drug use was also determined according to
patients’ declarations. Patients were asked if they had been
using ICS regularly in the previous year before pregnancy
and during pregnancy. The study was approved by the local
ethics committee. All patients gave verbal informed consent
to be included in the study.
Parameters
Gestational age was defined as the duration of the
pregnancy in days, and preterm delivery as birth occur-
ring before 37 completed weeks of gestation, according
to the classification system of the World Health
Organization. Small for gestational age (SGA) and low
birth weight (LBW) were defined as a birth weight
below the 10% percentile for each gender by gestational
age (completed weeks) and as a birth weight below 2,500 g,
respectively. The assessment of LBW was restricted to
deliveries after the 37th week of gestation. The Apgar score
cut-off value was 8 since adverse effects are associated
with Apgar scores < 8.
Statistical analysis
All analyses were performed using computer software
(SPSS version10:0; SPSS; Chicago, IL). Nominal values
are described as percentages. Descriptive statistics are
expressed as mean ± SD. Categorical data were tested
using the chi-square statistics. Mann–Whitney U test
was used for comparison of the continuous variables. A
P less than 0.05 was considered statistically significant.
Results
The two groups were statistically different in terms of
age and profession. Asthmatic pregnant women were older,
and in the asthmatic group there were more housewives
than in non-asthmatic one (Table 1).
Seven asthmatic women did not use any medication
for their asthma before and during pregnancy. While the
rate of regular asthma medication use was 32% (n = 8)
before pregnancy and 44% (n = 11) during pregnancy
term, the rate of irregular asthma medication use was
68% (n = 17) before pregnancy and 56% (n = 14) during
pregnancy term (p = 0.561). An increase of 12% was
detected in regular use of asthma medication, and this
was not statistically significant. In the group of asthmatic
pregnants affirming that they had been taking their
asthma drugs regularly before pregnancy, 87.5% (n = 7)
kept using their regular drug and attended regular follow
up for asthma during pregnancy. 23.5% (n = 4) of asthmatic
pregnants who used asthma medications irregularly before
pregnancy stated that they began to use asthmatic drugs
regularly during pregnancy.
Among asthmatic pregnant women, 52% (n = 13) used
inhaled anti-inflammatory agents, 40% (n = 10) used SABA
(at least two times a week), and 40% (n = 10) used
Table 1 Demographic features and pregnancy history
of subjects
Pregnants with
asthma n = 32
Pregnants without
asthma n = 121
Age, years (mean±SEM) 28.7±6.4 25.9±5.3*
Profession (housewife) n (%) 31 (96.9%) 100 (82.6%)*
Educational status
(primary school) n (%)
21 (65.6%) 72 (59.5%)




Gravity, median (min-max) 2 (1-7) 2 (1-7)
Parity, median (min-max) 2 (0–5) 1 (1-5)
Abortus, median (min-max) 0 (0–2) 0 (0–2)
*p<0.05.
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LABA, eight subjects used combination of ICS+LABA)
during pregnancy. The usage rates of asthma drugs
according to the medication class were not significantly
different between the periods before and after pregnancy
in asthmatic subjects. In this study the ICS and LABA
drugs used by patients were fluticasone or budesonide and
formeterol or salmeterol, respectively.
The rates of hospitalizations 13% (n = 4), emergency
visits 46.9% (n = 15), and systemic steroid use 18.8%
(n = 6) recorded in the previous year remained unchanged
during the pregnancy term [13% (n = 4), 46.9% (n = 15),
and 21.9% (n = 7), respectively].
According to the patients’ own evaluations, asthma
status improved in 28% of pregnant patients, remained
unchanged in 28%, and worsened in 44% of the subjects
during pregnancy.
There was no difference in terms of pregnancy/labour
complication, Apgar score, offspring malformation between
asthmatic and non-asthmatic pregnants (Table 2).
Discussion
Our results revealed that almost half of the pregnant
women with asthma used their controller drugs regularly
during pregnancy. Furthermore, the regular use of asthma
drugs increased during pregnancy when compared to theTable 2 Obstetric variables in pregnant women with and
without asthma
With asthma Without asthma p
Labour complication 9.4% 14.9% > 0.05
Pregnancy complication 28.1% 19.8% > 0.05
Score of APGAR 100% 97.5% >0.05
Mean birth weight (gr) 3315 3245 >0.05
Mean birth week 38.5 38.6 >0.05
Malformation 0% 2.5% >0.05pre-pregnant period. However, some clinical parameters,
such as hospital and emergency room admissions and the
use of oral steroids due to asthma, showed that asthma was
not controlled well enough in many asthmatic pregnants
during pregnancy.
One of the findings of our study was that asthma
medication use did not change in asthmatic pregnants,
whereas an increase of 12% was detected in regular
asthma medication use although it is not statistically
significant. This result is not consistent with previous
studies, which report a decrease in drug usage among
asthmatic pregnants [3,4]. In one study [3], 39% of
women were reported to discontinue or reduce asthma
medication use during pregnancy, mostly without
consulting with their doctor, mainly because of concerns
related to the safety of these drugs during pregnancy.
The most significant decrease in asthma medication use in
early pregnancy was relative to inhaled anti-inflammatory
agents and rescue corticosteroids, with a 23% and 54%
decrease, respectively. In the second trimester there was a
rebound in the use of inhaled and rescue corticosteroids,
although their use remained lower than that of pre-
pregnancy [4]. The inconsistency of our findings with
previous literature may be related to some of the fea-
tures of the group in our study. Asthma control seems
to be poor in approximately half of asthmatic pregnant
women before and during pregnancy according to the
rates of hospitalizations, emergency service visits, and
oral steroid usage. Consequently, they needed to use
medications regularly to keep their asthma in a more stable
state. Considering these evaluations, we can infer that poor
asthma control during pregnancy may positively influence
pregnant women to use their asthma medications.
It is widely accepted that treatment with asthma
medications is a safer option for pregnant women with
asthma than having asthma symptoms and exacerbations
[6]. Inhaled corticosteroids have been advocated as the
first line therapy for patients with asthma during preg-
nancy. There are several drugs that can be added to ICS,
i.e. short and long acting beta agonist bronchodilators,
which may be elected according to the severity of bron-
chial constriction and the frequency of crises. The use of
inhaled SABA, as required, is currently recommended for
all levels of asthma in pregnant women. However, there is
insufficient data currently available regarding the safety of
LABA during pregnancy although safety is considered
likely based on the inhalational route and the generally
reassuring data for SABA [7]. Any treatment for acute
asthma during pregnancy should follow recommended
guidelines since uncontrolled asthma increases the risk of
pregnancy complications (low birth weight and premature
delivery) more than the eventual medication risks to preg-
nancy [8-12]. In the present study a fairly high proportion
(40%) of pregnant women with asthma used LABA, and
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and LABA were given to achieve the control of the disease.
In this analysis, interviews with the patients were
performed within 24 hours from delivery. The patients
were asked about asthma related items, such as use of
asthma medications, number of hospitalizations, and emer-
gency department admissions. Although it looks like a limi-
tation in terms of over/under reporting of the questioned
items retrospectively, this evaluation enabled us to collect
information under real life conditions. If the patients had
been included in the study at the beginning of their preg-
nancy, they may have behaved more compliantly, and the
results of the study would not reflect reality.
There are many limitations of this study. Since this is
a cross sectional, questionnaire based study, all data
used in this study (like asthma diagnosis, regular drug
usage, hospitalization, emergency visit, systemic steroid
usage rates) depend on the patients’ statements. None of
the patients had been followed by the chest physicians in
the study before or during pregnancy for their asthma
management, thus we did not have chance to know their
management strategy and to check the accuracy of
their statements. And again since we did not follow up
information, asthma control status of the patients dur-
ing pregnancy was not clear. It was only evaluated
from patients’ perspective and we tried to put forward
an idea about asthma control of the patients depending
on the rates of hospitalization, emergency visit, and
systemic steroid usage. However, we believe that if the
patients had been followed by a physician of this study
during pregnancy, they would have reported data not
consistent with their usual behavior. Another important
limitation of this study is the small number of cases.
Although the small number of subjects limits us to make
firm conclusions, this first study gives information on drug
usage in asthmatic pregnant women in our country.Conclusion
In conclusion, regular use of asthma drugs increased
during pregnancy in our study. The uncontrolled condi-
tion of asthma before and during pregnancy and the idea
that asthma worsened during pregnancy might force the
patients to use medication more regularly. Therefore,
particular attention should be paid to the education of
physicians and asthmatic women, concerning asthma
control before and during pregnancy.Availability of supporting data
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